Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] price surged by 23.51 percent to reach at $0.1.
The one-year LXRX stock forecast points to a potential upside of 82.37. The average equity rating for LXRX stock is currently 2.17, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Lexicon Pharmaceuticals Inc [LXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $2.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 2.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on March 05, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 17, 2024, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $5, while Leerink Partners analysts kept a Outperform rating on LXRX stock.
The Average True Range (ATR) for Lexicon Pharmaceuticals Inc is set at 0.09, with the Price to Sales ratio for LXRX stock in the period of the last 12 months amounting to 6.02. The Price to Book ratio for the last quarter was 1.28, with the Price to Cash per share for the same quarter was set at 0.66.
LXRX Stock Performance Analysis:
Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.28. With this latest performance, LXRX shares gained by 32.06% in over the last four-week period, additionally sinking by -67.86% over the last 6 months – not to mention a drop of -74.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXRX stock in for the last two-week period is set at 54.47, with the RSI for the last a single of trading hit 59.24, and the three-weeks RSI is set at 50.83 for Lexicon Pharmaceuticals Inc [LXRX]. The present Moving Average for the last 50 days of trading for this stock 0.5626, while it was recorded at 0.4693 for the last single week of trading, and 1.2203 for the last 200 days.
Insight into Lexicon Pharmaceuticals Inc Fundamentals:
Lexicon Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.44 and a Current Ratio set at 5.44.
LXRX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lexicon Pharmaceuticals Inc go to 22.79%.
Lexicon Pharmaceuticals Inc [LXRX] Institutonal Ownership Details
There are presently around $84.11%, or 85.11%% of LXRX stock, in the hands of institutional investors. The top three institutional holders of LXRX stocks are: ARTAL GROUP S.A. with ownership of 175.1 million shares, which is approximately 56.3318%. FMR LLC, holding 38.69 million shares of the stock with an approximate value of $$64.99 million in LXRX stocks shares; and FMR LLC, currently with $$16.62 million in LXRX stock with ownership which is approximately 3.1818%.
